All News
Filter News
Found 760 articles
-
ImmunoPrecise Relocates European Subsidiary to LEED Certified Campus to Continue to Advance its Antibody Research Operations and Environmental Sustainability
1/18/2022
IMMUNOPRECISE ANTIBODIES LTD. announced the relocation of its IPA Europe Oss laboratories to a new multi-tenant biotech Center of Excellence at the Pivot Park Campus in Oss, Netherlands.
-
Data Published in Ocular Oncology and Pathology Demonstrates Highly Accurate Performance of DecisionDx®-UMSeq for Patients with Uveal Melanoma
1/12/2022
Data Published in Ocular Oncology and Pathology Demonstrates Highly Accurate Performance of DecisionDx®-UM Seq for Patients with Uveal Melanoma.
-
Advaxis Presents Updated Clinical Data from Ongoing Phase 1/2 Trial of ADXS-503 in NSCLC and Upcoming Milestones
1/11/2022
Advaxis, Inc. today announced updated data from the Company’s ongoing Phase 1/2 study evaluating ADXS-503 in combination with KEYTRUDA®.
-
Revolution Medicines Reports Progress Across Pipeline of Targeted Therapeutics for RAS-Addicted Cancers in Presentation at 40th Annual J.P. Morgan Healthcare Conference
1/11/2022
Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing novel targeted therapies for RAS-addicted cancers, today reported progress across its pipeline of targeted therapeutics spanning its RAS(ON) Inhibitor and RAS Companion Inhibitor portfolios.
-
HotSpot Therapeutics and Caris Life Sciences Announce Collaboration to Advance Precision Medicine Development for Difficult-to-Drug Therapeutic Targets
1/10/2022
HotSpot Therapeutics, Inc. and Caris Life Sciences® announced a strategic partnership to advance precision medicine approaches for HotSpot's emerging product portfolio.
-
Caris Life Sciences and HotSpot Therapeutics Announce Collaboration to Advance Precision Medicine Development for Difficult-to-Drug Therapeutic Targets
1/10/2022
Caris Life Sciences® and HotSpot Therapeutics, Inc. announced a strategic partnership to advance precision medicine approaches for HotSpot's emerging product portfolio.
-
Biopharma and life sciences companies from across the globe provide updates on their businesses and pipelines.
-
Nykode Therapeutics announces first subject dosed with its T cell focused next-generation SARS-CoV-2 vaccine candidate
12/28/2021
Nykode Therapeutics AS announced the first subject has been dosed with its T cell focused next-generation SARS-CoV-2 vaccine candidate in its VB-D-01 Phase 1/2 trial.
-
Band Ligators Market: Rise in Prevalence of Diseases such as Colon Cancer to Drive the Market
12/22/2021
Band ligators are surgical devices used for ligation of deep vessels and inaccessible parts. The medical device allows gastroenterologists to look into the oesophagus and rectal walls to detect tumors or hemorrhoids and remove them from the body.
-
MGI Contributes to Rapid Detection and Surveillance of COVID-19 Omicron Variant
12/15/2021
MGI Tech Co., Ltd. is playing an instrumental role in the global battle against the omicron variant of COVID-19 with its DNBSEQ™ and ATOPlex technologies.
-
Relay Therapeutics Announces Preclinical Data that Support Clinical Development of RLY-2608 as Both a Single Agent and in CombinationRLY-2608 combines with standard of care therapies to drive regressions in ER+/HER2- breast cancer models
12/10/2021
Relay Therapeutics, Inc. today shared additional preclinical data at the 2021 San Antonio Breast Cancer Symposium for RLY-2608, the first known allosteric, pan-mutant and isoform-selective PI3Kα inhibitor.
-
H3 Biomedicine Presents Investigational Data Update on H3B-6545 for Treatment of Locally Advanced or Metastatic Estrogen Receptor- positive, HER2-negative Breast Cancer at San Antonio Breast Cancer Symposium
12/8/2021
H3 Biomedicine Inc. today announced the presentation of two posters at the 2021 San Antonio Breast Cancer Symposium (SABCS) being held in a hybrid format on December 7- 10, 2021.
-
Quell Therapeutics scooped up $156 million in a Series B round this week. The company utilizes regulatory T cells to treat a variety of autoimmune and inflammatory diseases.
-
HotSpot Therapeutics Closes $100M Series C to Advance First-in-Class Allosteric Drug Discovery Platform to the Clinic
11/29/2021
Financing will accelerate HotSpot's transition into a clinical development company while enabling expansion of its product pipeline.
-
HotSpot Therapeutics to Present at the Piper Sandler 33rd Annual Healthcare Conference
11/16/2021
HotSpot Therapeutics, Inc. today announced that company leadership will deliver a corporate overview at the Piper Sandler 33rd Annual Healthcare Conference
-
Novel Blood Pressure Stabilization Therapy Presented at Neuroscience 2021
11/15/2021
ONWARD Medical N.V. (Euronext: ONWD), today announced Grégoire Courtine, Ph.D., Professor of Neuroscience at the Swiss Federal Institute of Technology (EPFL) and co-Director of NeuroRestore, demonstrated the effectiveness of ONWARD’s ARC Therapy to stabilize blood pressure after spinal cord injury during his Presidential Special Lecture at NEUROSCIENCE 2021.
-
Athenex Announces Exclusive License Agreement with National Cancer Institute to Utilize T Cell Receptors Targeting Mutated p53, KRAS, and EGFR for the Development of Autologous and Allogeneic Cell Therapies
11/9/2021
Athenex today announced a licensing agreement with the National Cancer Institute (NCI), an institute of the National Institutes of Health (NIH), to expand the development of T cell receptor (TCR) based allogeneic natural killer T (NKT) cell
-
Ziopharm Oncology Presents Preclinical Data Supporting TCR-T Library Approach at the Society for Immunotherapy of Cancer 2021 Annual Meeting
11/9/2021
Ziopharm Oncology, Inc. (“Ziopharm” or the “Company”) (Nasdaq: ZIOP), today announced the presentation of preclinical data highlighting the potential of neoantigen-specific TCR-T cells for the treatment of solid tumors at the Society for Immunotherapy of Cancer 2021 Annual Meeting.
-
HotSpot Therapeutics to Present New Data Indicating Successful Targeting of CBL-B at 2021 Society for Immunotherapy of Cancer Annual Meeting
11/9/2021
HotSpot Therapeutics, Inc., today announced new data validating its Smart Allostery™ platform in the elucidation and preclinical evaluation of a novel allosteric inhibitor of the E3 ubiquitin ligase CBL-B.
-
Lab Genomics Announces MolDX® Coverage for Follow It® Circulating Tumor DNA Assay in Partnership with Canexia Health
11/1/2021
Lab Genomics Announces MolDX® Coverage for Follow It® Circulating Tumor DNA Assay in Partnership with Canexia Health